601: Timing of Androgen Deprivation Therapy and Its Impact on Cancer-Specific Survival after Radical Prostatectomy: A Matched-Cohort Analysis

Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement. When biochemical recurrence (BCR) occurs, salvage radiotherapy (SRT) is performed. The benefit in terms of BCR-free survival (FS) and metastasis-FS by adding 6 months of androgen deprivation therapy (ADT) compared with SRT only has already been established. Retrospective evidence suggests that a longer schedule of ADT may be more beneficial compared with 6 months. This multicenter open-label randomized trial will include patients who need SRT after experiencing BCR post-radical prostatectomy with lymphadenectomy and pN0-status. Patients will be randomized for ADT duration (6 vs 24 months). Primary end point is distant metastasis-FS. Clinical Trial Registration: NCT04242017 ( ClinicalTrials.gov )

Download Full-text

Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer

International Journal of Urology ◽

10.1111/iju.12047 ◽

2012 ◽

Vol 20 (8) ◽

pp. 798-805 ◽

Cited By ~ 1

Author(s):

Brian J Linder ◽

Stephen A Boorjian ◽

Eric C Umbreit ◽

Rachel E Carlson ◽

Laureano J Rangel ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

High Risk ◽

Radical Prostatectomy ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

High Risk Prostate Cancer ◽

Risk Prostate Cancer ◽

Comorbidity Status

Download Full-text

Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50–7

European Urology ◽

10.1016/j.eururo.2016.04.039 ◽

2016 ◽

Vol 70 (6) ◽

pp. e159

Author(s):

William C. Jackson ◽

Matthew J. Schipper ◽

Felix Y. Feng

Keyword(s):

Radiation Therapy ◽

Radical Prostatectomy ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Letter To The Editor

Download Full-text

NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer

Biomedicines ◽

10.3390/biomedicines9050528 ◽

2021 ◽

Vol 9 (5) ◽

pp. 528

Author(s):

Shu-Pin Huang ◽

Yei-Tsung Chen ◽

Lih-Chyang Chen ◽

Cheng-Hsueh Lee ◽

Chao-Yuan Huang ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Tyrosine Kinases ◽

Multiple Testing ◽

Cox Regression ◽

Progression Free Survival ◽

Androgen Deprivation ◽

Nucleotide Polymorphisms ◽

Multiple Testing Correction ◽

Cancer Specific Survival

Neuregulins (NRGs) activate receptor tyrosine kinases of the ErbB family, and play essential roles in the proliferation, survival, and differentiation of normal and malignant tissue cells. We hypothesized that genetic variants of NRG signalling pathway genes may influence treatment outcomes in prostate cancer. To test this hypothesis, we performed a comprehensive analysis to evaluate the associations of 459 single-nucleotide polymorphisms in 19 NRG pathway genes with cancer-specific survival (CSS), overall survival (OS), and progression-free survival (PFS) in 630 patients with prostate cancer receiving androgen-deprivation therapy (ADT). After multivariate Cox regression and multiple testing correction, we found that NRG1 rs144160282 C > T is significantly associated with worsening CSS, OS, and PFS during ADT. Further analysis showed that low expression of NRG1 is closely related to prostate cancer, as indicated by a high Gleason score, an advanced stage, and a shorter PFS rate. Meta-analysis of 16 gene expression datasets of 1,081 prostate cancer samples and 294 adjacent normal samples indicate lower NRG1 expression in the former compared with the latter (p < 0.001). These results suggest that NRG1 rs144160282 might be a prognostic predictor of the efficacy of ADT. Further studies are required to confirm the significance of NRG1 as a biomarker and therapeutic target for prostate cancer.

Download Full-text